Menopause and the Cardiovascular Transition

Menopause and the Cardiovascular Transition

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

The menopause transition is the most under-utilized window for cardiovascular prevention in a woman’s life. The cardiovascular changes that concentrate in the years around the final menstrual period are real, measurable, and largely absent from routine midlife care. Most women learn that menopause matters cardiovascularly only after a clinical event makes it obvious — by which point the window has narrowed.

The atherogenic lipid markers — total cholesterol, LDL cholesterol, apolipoprotein B — change at menopause in a step rather than a gradual slope, in the year window centered on the final menstrual period. (2) Body composition shifts toward visceral fat. Insulin sensitivity declines. Endothelial function deteriorates. Arterial stiffness rises. Women who reach menopause earlier than typical — before age 40, or surgically — carry meaningfully higher cardiovascular risk than women at typical ages. (3,4,5) The 2020 American Heart Association scientific statement formally recognized this transition as a critical window for prevention. (1) This article maps the biology of perimenopause, the specific implications of earlier menopause, and what the midlife cardiovascular visit should cover.

The Phases of the Menopause Transition

Premenopause. Regular menstrual cycles. Reproductive phase.

Perimenopause (the menopause transition itself). Begins with the first persistent changes in cycle length or pattern. Ends one year after the final menstrual period. Typically begins in the mid-to-late 40s and lasts on average four to seven years. Estradiol levels during this phase are highly variable rather than uniformly declining; some cycles produce high estradiol, others very low. Follicle-stimulating hormone rises progressively. The cardiovascular changes discussed below concentrate in this phase and the immediate postmenopausal period.

Menopause. Defined retrospectively as twelve consecutive months without menstruation. The median age in high-income countries is approximately 50 to 51, with the typical range spanning ages 45 to 55. (1)

Postmenopause. The phase that follows.

Premature menopause (before age 40, sometimes called primary ovarian insufficiency), early menopause (40 to 44), and surgical menopause (induced by bilateral oophorectomy at any age) each carry greater cardiovascular implications than natural menopause at typical ages. Surgical menopause produces an abrupt rather than gradual loss of ovarian estrogen, which is part of why its cardiovascular signal is stronger than natural menopause at the same age.

What Changes Cardiovascularly

The 2020 American Heart Association scientific statement on menopause and cardiovascular disease was the first major society document to formally characterize the menopause transition as a period of accelerated cardiovascular risk. (1) It drew on two decades of longitudinal cohort data — most prominently the Study of Women’s Health Across the Nation, a multiethnic study that followed 3,302 women aged 42 to 52 through the transition. The findings are specific.

The Lipid Shift Is Real and It Happens at Menopause, Not Age

The Matthews 2009 SWAN analysis asked a clean methodological question: when cardiovascular risk markers worsen in midlife women, is that change driven by getting older or by going through menopause? The two answers point to different prevention strategies, and the data say something specific about each marker.

Among the 1,054 women who reached the final menstrual period during SWAN follow-up, most risk markers — blood pressure, glucose, insulin, hemostatic factors, high-sensitivity C-reactive protein — followed a linear age-related trajectory. Whether a woman was premenopausal, perimenopausal, or postmenopausal made no detectable difference to their slope; what changed them was time. (2)

Three markers behaved differently. Total cholesterol, LDL cholesterol, and apolipoprotein B all rose in a step pattern centered on the final menstrual period — substantially in the year before, substantially in the year after, and then resumed an aging-related slope. (2) The pattern was robust across White, African American, Hispanic, Japanese, and Chinese participants. A subsequent SWAN analysis confirmed the downstream consequence: the size of the lipid jump around the final menstrual period predicted subsequent carotid plaque burden. Greater LDL increases around the FMP, greater likelihood of subclinical atherosclerosis years later. (8)

Matthews et al., 2009 (SWAN; n = 1,054 women followed to final menstrual period).

What this means in practice: the lipid panel that looked unremarkable at 48 may show meaningful changes at 52. The change is not a measurement artifact, not a sign of dietary lapse, and not something that can be reliably distinguished from “aging” without knowing where you are in the menopause transition. It belongs in the cardiovascular conversation.

Body Composition Shifts, Even If Your Weight Doesn’t

Body fat redistributes during the menopause transition from a subcutaneous gluteofemoral pattern toward an increased proportion of visceral adipose tissue — the fat that surrounds internal organs in the abdominal cavity. The shift is independent of total weight change in many women. Fat redistributes even when the scale does not move. (1)

The cardiovascular consequence is metabolic. Visceral fat is biologically distinct from subcutaneous fat. It is more lipolytically active, secretes more pro-inflammatory cytokines, and is more closely linked to insulin resistance, dyslipidemia, and hypertension. The shift toward visceral adiposity is part of why insulin sensitivity often declines during and after the transition, and part of why type 2 diabetes prevalence rises in the postmenopausal years.

Vascular Function Deteriorates

Three changes in how blood vessels work have been documented through and after the transition. Endothelial function — the ability of the vessel wall to relax in response to flow and other stimuli — declines, correlated more with estrogen loss than with chronological age. (1) Arterial stiffness, measured as how rapidly a pressure wave travels through the arterial tree, increases. (1) Carotid intima-media thickness — an ultrasound measure of early plaque buildup — progresses faster than aging alone would predict, with the lipid changes around the final menstrual period predicting that progression. (1,8)

None of these alone is dramatic. Together they describe a transition into a higher-risk vascular state. The 2020 AHA statement frames this as a shift in physiologic state rather than as menopause causing disease — and that framing matters, because the implication is that the disease was being built across the prior decades and the transition is when it becomes visible.

Earlier Menopause Carries Greater Cardiovascular Risk

The cardiovascular implications of menopause are not uniform across age. The earlier a woman reaches menopause, the higher her subsequent cardiovascular risk, in a graded relationship documented across three of the strongest meta-analyses and cohort studies in the field.

Muka 2016 (JAMA Cardiology) pooled 32 observational studies covering 310,329 women. Women who reached menopause before age 45 had a relative risk of 1.50 for coronary heart disease, 1.11 for fatal coronary heart disease, 1.19 for cardiovascular mortality, and 1.12 for all-cause mortality compared with women who reached menopause at age 45 or later. (3) The stroke association was not statistically significant.

Zhu 2019 (Lancet Public Health) pooled individual patient data from 301,438 women across 15 studies through the InterLACE consortium. The cardiovascular signal was substantially stronger when restricted to events before age 60, and attenuated to non-significance by age 70. (4)

Zhu et al., 2019; InterLACE pooled analysis.

Honigberg 2019 (JAMA) analyzed 144,260 women in the UK Biobank. Natural premature menopause was associated with a hazard ratio of 1.36 for a composite cardiovascular outcome that included coronary artery disease, heart failure, valvular disease, atrial fibrillation, ischemic stroke, peripheral artery disease, and venous thromboembolism. Surgical premature menopause carried a higher hazard ratio of 1.87. (5)

The mechanisms operate in combination. A woman whose menopause occurs at 38 spends roughly 12 additional years in the postmenopausal cardiovascular environment compared with a woman whose menopause occurs at 50 — accumulating exposure to the lipid, vascular, and metabolic changes described above. Some of the signal also reflects shared upstream factors: genetics, autoimmune conditions, prior chemotherapy or radiation, smoking, and several reproductive factors influence both age at menopause and cardiovascular risk. And earlier loss of estrogen-related vascular protection — endothelial nitric oxide signaling, the effects discussed in Article 1 of this series — likely contributes directly.

The clinical implication is direct. The 2019 American College of Cardiology and American Heart Association primary prevention guideline lists premature menopause (before age 40) as a formal “risk-enhancing factor” that may justify reclassifying a woman’s cardiovascular risk category and intensifying prevention. (6) This is the same framework that incorporates adverse pregnancy outcomes (Article 3 of this series). A woman with premature menopause whose calculated ten-year cardiovascular risk falls in a borderline range may, on the strength of her menopause history alone, be a candidate for more intensive prevention.

For women with primary ovarian insufficiency specifically, the American College of Obstetricians and Gynecologists recommends systemic hormone therapy until the average age of natural menopause is reached, explicitly to reduce the long-term cardiovascular, bone, and other health consequences of premature estrogen loss. (7) The risk-benefit calculation for hormone therapy in this group is fundamentally different from the calculation for postmenopausal hormone therapy in women at typical ages — a distinction Article 6 of this series treats in depth.

The Prevention Window

The convergence of the findings above supports something the 2020 American Heart Association scientific statement made explicit: the perimenopausal years are when cardiovascular prevention has the most leverage. (1)

The cardiovascular changes concentrate in this window. The lipid shifts, the body composition changes, the early vascular dysfunction — none of these is spread evenly across the lifespan. They cluster in the years surrounding the final menstrual period. Interventions targeted to that window have the most to address.

The changes are modifiable. None of the cardiovascular shifts associated with the menopause transition is inevitable. Lifestyle interventions — physical activity, dietary pattern, weight management, sleep, smoking status — modify each of the relevant outcomes. Lipid-lowering pharmacotherapy when indicated is effective. The vascular function changes are slower to reverse than the lipid changes, but the slope of further deterioration can be substantially altered.

The conversation is not happening enough. The 2020 American Heart Association statement called this out explicitly because the field had been failing women on this point for decades. Cardiovascular risk assessment in midlife women has historically been deferred — to age 60, to age 65, to whenever a clinical event finally makes the conversation unavoidable. By the time the conversation happens, much of the most modifiable risk has accumulated. The argument of the AHA statement, and of the 2019 ACC/AHA prevention guideline, is that the conversation should move earlier into the routine adult preventive care pathway for women. (1,6)

What the conversation should include is not exotic. Blood pressure. A full lipid panel (including LDL cholesterol and apolipoprotein B when available). Glucose. Weight and body composition. Physical activity. Dietary pattern. Tobacco use. Family history. The reproductive history elements covered in Articles 3 and 4 of this series. What is new is the timing — the recognition that midlife is not too early.

What Your Midlife Visit Should Cover

If you are in perimenopause or the early postmenopausal years, the cardiovascular elements of your care should include the following. Most of these are not difficult to obtain. Most of them are not in routine practice for midlife women, which is why the 2020 AHA statement exists.

A focused cardiovascular evaluation in the perimenopausal years. Blood pressure (multiple measurements over time, not a single reading). A fasting lipid panel that includes LDL cholesterol; apolipoprotein B if available. Fasting glucose or HbA1c. Body composition, not just weight on a scale. The lipid panel that was unremarkable at age 48 may have shifted by age 52. A baseline before the transition is useful; a follow-up after the transition stabilizes is at least as useful.

Explicit attention to changes around the final menstrual period. If your cholesterol has shifted in the year before or after your final menstrual period, that shift is informative about your cardiovascular risk and worth treating as a signal rather than a coincidence with aging.

Earlier prevention conversations if your menopause was earlier. Premature menopause (before 40) is a formal risk-enhancing factor in current guidelines. Early menopause (40 to 44) carries meaningful though somewhat lesser implications. Surgical menopause at any age carries greater implications than natural menopause at the same age. Each of these belongs explicitly on the chart and in the conversation.

Recognition that the transition itself is not a treatment indication. The menopause transition does not produce cardiovascular disease. It reveals the trajectory that decades of cumulative exposure have shaped. Lifestyle and risk factor modification remain the foundation of prevention; hormone therapy is a separate question with its own risk-benefit framework, which Article 6 of this series addresses in depth.

Cardiovascular questions that get raised by you if your clinician does not raise them. The AHA statement exists because the conversation has been absent from routine care. Knowing what to ask is part of getting the care.

The Bottom Line

The menopause transition is a period of accelerated cardiovascular risk that has been formally documented by the 2020 American Heart Association scientific statement, the 2019 ACC/AHA primary prevention guideline, and two decades of longitudinal cohort data. The lipid changes that occur in the year around the final menstrual period are real and inconsistent with chronological aging alone. Body composition, insulin sensitivity, endothelial function, and arterial stiffness all shift in this window. Premature menopause and surgical menopause carry meaningfully higher cardiovascular risk than natural menopause at typical ages, with the strongest signal for events before age 60.

The conversation that should accompany these changes — about lipids, blood pressure, glucose, body composition, lifestyle, and the integrated cardiovascular risk profile — has historically not happened in routine midlife care. The perimenopausal years are when cardiovascular prevention has the most leverage. The midlife visit that does not include this conversation is incomplete.

The menopause transition is not a cardiovascular disease. It is the cardiovascular conversation that has been waiting for the right moment to happen.

Next: Article 6 addresses menopausal hormone therapy — what the Women’s Health Initiative actually showed, the timing hypothesis, the contemporary evidence, and how to think about hormone therapy when the conversation has been distorted for two decades.

Key Terms

Apolipoprotein B (ApoB): A structural protein found in atherogenic lipoprotein particles, including LDL and very-low-density lipoprotein. Each atherogenic particle contains one apolipoprotein B molecule, so apolipoprotein B measures the number of atherogenic particles in circulation. Rises during the menopause transition independent of chronological aging.

Arterial stiffness: A measure of how rigid or non-distensible the arterial wall is, commonly assessed by carotid-femoral pulse wave velocity. Increases during the menopause transition and is an independent predictor of cardiovascular events.

Carotid intima-media thickness (cIMT): An ultrasound measurement of the thickness of the inner two layers of the carotid artery wall, used as an imaging marker of subclinical atherosclerosis.

Early menopause: Menopause occurring between ages 40 and 44.

Endothelial function: The capacity of the inner lining of blood vessels to regulate vessel tone, blood flow, inflammation, and thrombosis. Declines during the menopause transition.

Final menstrual period (FMP): The last menstrual period, which dates menopause retrospectively after twelve consecutive months without further menstruation. Many of the cardiovascular changes attributable to the menopause transition concentrate in the year before and after the final menstrual period.

Follicle-stimulating hormone (FSH): A pituitary hormone that rises progressively during the menopause transition as the ovaries become less responsive to it. Often used clinically as a marker of menopausal status, though menstrual cycle patterns are the more reliable indicator.

Menopause transition (MT): The perimenopausal phase, from the first persistent menstrual cycle changes to one year after the final menstrual period. Typically lasts four to seven years.

Perimenopause: Used interchangeably with menopause transition in much of the literature.

Postmenopause: The phase beginning twelve months after the final menstrual period and continuing for the rest of life.

Premature menopause / Primary ovarian insufficiency (POI): Menopause occurring before age 40. “Primary ovarian insufficiency” is now generally preferred over “premature ovarian failure” in clinical usage because it more accurately captures the variable nature of ovarian dysfunction.

Study of Women’s Health Across the Nation (SWAN): A multicenter, multiethnic longitudinal cohort study that enrolled 3,302 women aged 42 to 52 and followed them through the menopause transition. Established much of the modern evidence base for the cardiovascular changes attributable to the transition.

Surgical menopause: Menopause induced by bilateral oophorectomy at any age. Produces an abrupt loss of ovarian estrogen and carries greater cardiovascular implications than natural menopause at the same age.

Visceral adiposity: Fat distributed within the abdominal cavity surrounding internal organs, as opposed to subcutaneous fat distributed under the skin. Increases during the menopause transition even when total body weight is stable.

References

1. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation.2020;142(25):e506–e532.
2. Matthews KA, Crawford SL, Chae CU, et al. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009;54(25):2366–2373.
3. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776.
4. Zhu D, Chung HF, Dobson AJ, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019;4(11):e553–e564.
5. Honigberg MC, Zekavat SM, Aragam K, et al. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411–2421.
6. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–e232.
7. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstet Gynecol. 2017;129(5):e134–e141.
8. Matthews KA, El Khoudary SR, Brooks MM, et al. Lipid changes around the final menstrual period predict carotid subclinical disease in postmenopausal women. Stroke. 2017;48(1):70–76.